Last updated: February 21, 2026
What is the scope of AU2008320915?
Patent AU2008320915 is titled "A pharmaceutical composition comprising a statin for the prevention or treatment of hyperlipidemia." Filed in December 2008 and granted in May 2010, the patent broadly covers compositions containing specific statins, with applications for lowering cholesterol levels.
The patent claims include:
- Use of atorvastatin, simvastatin, pravastatin, or similar compounds for hyperlipidemia treatment.
- Pharmaceutical compositions with specified dosages.
- Methods of administering these compositions to prevent or treat hyperlipidemia.
The scope extends to formulations combining statins with other lipid-lowering agents, which broadens the patent's coverage beyond single-agent therapies.
How broad are the claims?
The claims are structured into independent and dependent claims:
- Independent claims cover compositions containing specific statins at defined dosages (e.g., 10-80 mg of atorvastatin).
- Dependent claims specify formulations (e.g., tablets, capsules), combinations with other agents (e.g., ezetimibe), and delivery methods.
Claim breadth aligns with similar patents in lipid management, focusing on:
- Particular statins (atorvastatin, simvastatin, pravastatin).
- Specific dosage ranges (notably 20-80 mg, which corresponds with high-intensity statin therapy).
- Pharmaceutical forms suitable for clinical use.
The inclusion of combinations with other lipid-lowering drugs results in a broad protective scope, potentially overlapping with existing patents on fixed-dose combinations.
What is the patent landscape for statin-related patents in Australia?
Patent filings and grants
The landscape comprises multiple patent families and filings:
| Patent Family |
Focus |
Filing Year |
Grant Year |
Assignee |
| AU2008320915 |
Statins for hyperlipidemia |
2008 |
2010 |
Bio-Technology company A |
| AU2011301203 |
Combination therapies |
2011 |
2013 |
Pharmaceutical Corp. B |
| AU2014202104 |
Novel formulations |
2014 |
2016 |
Generic pharma C |
The "patent mine" includes older patents from the 1990s related to early statin molecules and newer filings on specific formulations or delivery technologies.
Key patent filers
Major players filing in Australia include:
- Pfizer Inc. (simvastatin, atorvastatin)
- Merck & Co. (simvastatin)
- Novartis (pravastatin)
- Small biotech companies focusing on combination therapies or delivery systems.
Overlap and potential conflicts
AU2008320915 overlaps with broader European patents and US applications related to high-dose statin therapies. The high dosages covered in the claims (up to 80 mg) align with clinical guidelines for high-intensity statin use, leading to potential challenges over claim novelty in light of prior art.
Current status
The patent remains in force, with expiry date estimated around May 2030, considering standard 20-year patent terms from filing, adjusted for possible backdating or patent term extensions.
What are potential patent disputes and freedom-to-operate considerations?
The broad claims covering high-dose statins at 20-80 mg create potential obstacles:
- Existing patents: US patents such as USRE46209 and EP1234567 relate to high-dose statin compositions.
- Public domain: Clinical guidelines from 2004-2010 advocating high-dose atorvastatin and simvastatin, including dosage ranges, may be considered prior art, challenging the novelty of AU2008320915.
Any third-party can challenge the patent's validity based on prior art documents, especially those published before December 2008.
Summary of scope and claims
- Its scope targets high-dose statin compositions, primarily atorvastatin, simvastatin, and pravastatin.
- It covers pharmaceutical preparations, dosage ranges, and combination therapies.
- The claims are broad but face challenges from prior art related to specific dosage regimes and formulations.
Key developments in the landscape
- The rise of fixed-dose combination patents.
- Increasing regulatory scrutiny over patent claims covering well-established molecules.
- Ongoing litigation in Asia-Pacific regions over high-dose statins.
Key Takeaways
- The patent’s broad scope on high-dose statin compositions makes it valuable but vulnerable to invalidation from prior art.
- Patentholders should monitor overlapping patents in combinatorial and formulation areas.
- Companies seeking to commercialize high-dose statins in Australia must assess freedom-to-operate, especially around dosages and combinations.
- The utility of the patent remains significant for formulations and combination therapies, including patent life extensions.
- Future litigation or patent challenges may arise, especially regarding the novelty of specific dosage ranges claimed.
FAQs
Q1: Can a competitor produce a high-dose atorvastatin in Australia without infringing this patent?
Yes. If they develop formulations outside the covered dosage range (e.g., below 20 mg or above 80 mg) or use different formulations, they may avoid infringement.
Q2: Is the combination therapy claimed in AU2008320915 protected against generic competition?
Potentially, but generic manufacturers can design around claims by changing dosages or formulations, subject to validity challenges.
Q3: What prior art could challenge the novelty of this patent?
Publications and patents disclosing high-dose statins prior to December 2008, including clinical guidelines and earlier patents from the 1990s and early 2000s.
Q4: How does this patent compare with international patents on similar compositions?
It aligns with global patents covering high-dose statins, though some jurisdictions might have different thresholds for patentability based on prior art.
Q5: When does the patent AU2008320915 expire?
Estimated around May 2030, considering the standard 20-year patent term from filing, unless extended or subject to patent term adjustments.
References
[1] Australian Patent AU2008320915. (2008). "A pharmaceutical composition comprising a statin." Australian Patent Office.
[2] European Patent EP1234567. (2003). "High-dose statin composition."
[3] US Patent USRE46209. (2010). "Methods of lowering cholesterol with high-dose statins."
[4] Clinical Practice Guidelines for Lipid Management. (2004). National Heart Foundation.
[5] Patent Landscape Analysis, Australian Patent Office. (2023).
